Merck, Eli Lilly, and Biogen committed over $12 billion in recent acquisitions, including Merck's $5.7B-$6.7B deal for Terns Pharmaceuticals, Eli Lilly's $6.3B acquisition of Centessa Pharmaceuticals, and Biogen's purchase of Apellis Pharmaceuticals.12
This M&A wave is described as a dominant trend in oncology biotech, accelerating capital deployment amid patent cliffs and AI-biology partnerships like Insilico Medicine’s $2.75B Lilly deal.1
Post-Hoc Live discussions highlight improving biotech sentiment, with expectations of continued M&A activity due to low valuations and market recovery, as noted in Endpoints News and HBM Healthcare outlooks.34
Additional deals include Novartis’ up to $2B for Excellergy and Gilead’s $2.1B for Ouro Medicines, pushing total biopharma spending beyond $20B.2
The sector shows strategic capital use for pipeline bolstering, regulatory wins, and clinical advancements.12
Sources:
1. https://oncodaily.com/techology/ai479711
2. https://www.biospace.com/business/biopharma-m-a-heats-up-rare-diseases-win-three-approvals-wave-crashes